300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: BioLizard Appoints Matthew Hall as Director of Business Development

EQS-News: BioLizard nv / Key word(s): Personnel
BioLizard Appoints Matthew Hall as Director of Business Development

18.04.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


BioLizard Appoints Matthew Hall as Director of Business Development

  • Matthew G. Hall, PhD, brings over a decade of experience in strategic partnerships and BD within the biotech and pharmaceutical sectors, with a particular focus on leveraging AI-driven solutions.
  • Appointment strengthens BioLizards’ position in the strategically important Swiss market, where the company recently established a new office.
  • BioLizard is the trusted go-to partner for data strategy and execution with companies across the range from drug discovery to clinical research and diagnostics. The company has a uniquely qualified team, combining expertise in biology and computer sciences.

Lausanne (Switzerland) and Ghent (Belgium), April 18, 2024 – BioLizard, the bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry, today announced the appointment of Matthew Hall, PhD, as Director of Business Development. Matthew's regional insights, gained from more than a decade as an insider in the Swiss biotech sector, combined with his expertise in AI and biology, make him a perfect fit for the BioLizard team. His unique profile and global network will further empower the company to expand and strengthen its presence in Switzerland and other key markets.

Liesbeth Ceelen, PhD, CEO of BioLizard, said: “We are delighted to welcome Matthew Hall to our team of ‘Lizards’ – as we like to call our employees – as Director of Business Development. His proven track record in biotech and strategic business development aligns perfectly with BioLizard’s mission to drive digital transformation across the life sciences sector. Deeply rooted in the Lausanne area and with an established regional and global network, he will be vital for our company as we build out our foothold at Biopôle, one of the largest biotech hubs in Switzerland and exciting pool for talent. With Matthew on board, we are very confident in our ability to further expand our presence in this crucial market and beyond.”

Matthew Hall, PhD, Director of Business Development at BioLizard, commented: “I'm excited to join BioLizard’s world-class team at the intersection of life sciences, bioinformatics, and AI/ML innovation. My focus will be on strategically expanding our business by fostering win-win partnerships that leverage our unique strengths in AI, data analysis and biology. I look forward to bridging client needs with our cutting-edge capabilities, transforming complex data into actionable insights. Next week, we will attend the Swiss Biotech Day, where I look forward to introducing BioLizard to my network. I am confident that we can bring great value to companies in the region, and I’m also excited about hosting our own events in the near future to understand and address our customer’s needs.”

Matthew brings extensive sector experience to BioLizard, having held leadership roles in multiple cutting-edge startups. As Head of Product Development at LAGOSTA, Matthew has played a key role in delivering a pharma/biotech compliant natural polymer to market. Previously, he was the Director of Strategic Partnerships at Distalmotion, a Lausanne-based surgical robotics company, where he supported a CHF 90 million Series E financing and drove the company’s scale-up efforts. As a Senior Project Leader AI at Distalmotion, he was responsible for evaluating and implementing data management, analytics, AI/ML, and simulator solutions. His experience also spans senior roles at QuartzBio as Senior Director Business Development, Data Integration & AI strategy and notably as CEO, Co-founder, and Board member at SimplicityBio SA, where he guided the company to profitability and oversaw its successful acquisition by Precision for Medicine Ltd. Matthew earned his PhD in Molecular and Cellular Neurobiology from Université de Lausanne.

+++++++++
Meet Matthew Hall and the BioLizard team at the on April 22-23 in Basel, Switzerland. 
Book a 1o1 meeting via the or get in touch with us directly. 
+++++++++

About BioLizard

BioLizard is a leading multi-national bioinformatics, data analytics and data management service and consulting company heading digital transformation in the life sciences industry. Headquartered in Ghent, Belgium, BioLizard is the trusted go-to partner for data strategy and execution with companies across the range from drug discovery to clinical research and diagnostics as well as animal health and food & agriculture. BioLizard accommodates a uniquely qualified team of 50+ experts, “The Lizards”, who bring together their expertise and abilities covering data management, software engineering, bioinformatics, advanced data analytics, and AI. Their joint backgrounds in biology and computer sciences enables them to apply specialist understanding to each client’s data environment, to provide insights and tools that are aligned with the client’s goals and maximize R&D return on investment. With the proprietary BioVerse platform BioLizard takes the next step in providing bespoke software solutions by tailoring its established programs towards specific client needs. For further information, please visit and follow us on .
 

Contact
BioLizard nv
Liesbeth Ceelen, PhD
Phone: 2
E-mail:
Media Inquiries
MC Services AG
Eva Bauer
Phone: +49 (0)89 2102280
E-mail:


18.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: BioLizard nv
Ottergemsesteenweg Zuid 808 bus B511
9000 Gent
Belgium
E-mail:
Internet:
EQS News ID: 1882889

 
End of News EQS News Service

1882889  18.04.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1882889&application_name=news&site_id=research_pool
EN
18/04/2024

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage

Emittent / Herausgeber: ibw – Informationszentrale der Bayerischen Wirtschaft e. V. / Schlagwort(e): Sonstiges/Sonstiges vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage 10.04.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. vbw zum Koalitionsvertrag: Gute Grundlage Brossardt: „Koalitionsvertrag schafft Planungssicherheit und setzt Wachstumsimpulse“  Bertram Brossardt, Hauptgeschäftsführer der vbw – Vereinigung der Bayerischen Wirtschaft e. V.: (München, 09.04.2025). Wir freuen uns, dass jetzt der Weg frei ist f...

 PRESS RELEASE

Aquis Stock Exchange - suspension of trading

Aquis Stock Exchange Aquis Stock Exchange - suspension of trading 10-Apr-2025 / 07:00 GMT/BST The issuer is solely responsible for the content of this announcement. The following securities are suspended from trading on the Aquis Growth Market from 08.00, 10 April 2025, at the request of the company: Richmond Hill Resources Plc Ordinary Shares Symbol: SHNJ ISIN: GB00BNTBWF32 The Regulation Department Aquis Stock Exchange Floor 2, 63 Queen Victoria Street, EC4N 4UA Tel: 0203 597 6361 Email:  Website:  Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The i...

 PRESS RELEASE

EQS-News: CO2Coin one of the most successful crypto investments of the...

Issuer: Clima4Future Ltd. / Key word(s): Cryptocurrency / Blockchain/Market Launch CO2Coin one of the most successful crypto investments of the coming decades. 10.04.2025 / 04:55 CET/CEST The issuer is solely responsible for the content of this announcement.     CO2Coin is going through a phase of phenomenal growth. A year ago the price was just €1, today it is around 270 USDT - an increase in value that illustrates the enormous potential of this unique project. This development reflects the crypto community's growing interest in sustainable investments. Clima4Future Lt...

 PRESS RELEASE

EQS-News: CO2Coin eine der erfolgreichsten Krypto-Investitionen der ko...

Emittent / Herausgeber: Clima4Future Ltd. / Schlagwort(e): Kryptowährung / Blockchain/Markteinführung CO2Coin eine der erfolgreichsten Krypto-Investitionen der kommenden Jahrzehnte. 10.04.2025 / 04:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Der CO2Coin hat einen beeindruckenden Kursanstieg erlebt. Vor einem Jahr lag der Kurs noch bei 1 €, heute liegt er bei rund 270 USDT - eine Wertsteigerung, die das enorme Potenzial dieses einzigartigen Projekts verdeutlicht. Diese Entwicklung spiegelt das wachsende Interesse der Krypto-Com...

 PRESS RELEASE

EQS-News: Zimbabwe Government Delivers on Commitment: Compensation of ...

EQS-News: Zimbabwe Ministry of Finance, Economic Development and Investment Promotion / Key word(s): Miscellaneous Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences 09.04.2025 / 20:20 CET/CEST The issuer is solely responsible for the content of this announcement. In line with the GCD agreement, the FFOs receive 1 per cent of their claim in cash, with the balance being paid through US$ denominated Treasury bonds with a 2 per cent coupon and maturities of 2 to 10 years HARARE, Zimbabwe, April 9, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch